再発性悪性神経膠腫:治療薬開発パイプライン動向(2016年下半期版)

【英語タイトル】Recurrent Malignant Glioma - Pipeline Review, H2 2016

Global Markets Directが出版した調査資料(DATA70209257)・商品コード:DATA70209257
・発行会社(調査会社):Global Markets Direct
・発行日:2016年12月30日
・ページ数:45
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における再発性悪性神経膠腫の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・再発性悪性神経膠腫の概要
・再発性悪性神経膠腫治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・再発性悪性神経膠腫パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・再発性悪性神経膠腫治療薬開発に取り組んでいる企業:企業別製品パイプライン
・再発性悪性神経膠腫治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Recurrent Malignant Glioma – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma – Pipeline Review, H2 2016, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.

Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Recurrent Malignant Glioma Overview 6
Therapeutics Development 7
Pipeline Products for Recurrent Malignant Glioma – Overview 7
Pipeline Products for Recurrent Malignant Glioma – Comparative Analysis 8
Recurrent Malignant Glioma – Therapeutics under Development by Companies 9
Recurrent Malignant Glioma – Therapeutics under Investigation by Universities/Institutes 10
Recurrent Malignant Glioma – Pipeline Products Glance 11
Clinical Stage Products 11
Recurrent Malignant Glioma – Products under Development by Companies 12
Recurrent Malignant Glioma – Products under Investigation by Universities/Institutes 13
Recurrent Malignant Glioma – Companies Involved in Therapeutics Development 14
2-BBB Medicines BV 14
AbbVie Inc 15
DNAtrix Inc 16
GtreeBNT Co Ltd 17
Recurrent Malignant Glioma – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
2B3-101 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Cellular Immunotherapy for Oncology – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Cellular Immunotherapy for Recurrent Malignant Glioma – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Cellular Immunotherapy to Target EphA2 for Recurrent Malignant Glioma – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Cellular Immunotherapy to Target IL-13 for Malignant Glioma – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
depatuxizumab mafodotin – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
disufenton sodium – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DNX-2401 – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Recurrent Malignant Glioma – Dormant Projects 42
Recurrent Malignant Glioma – Discontinued Products 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables
Number of Products under Development for Recurrent Malignant Glioma, H2 2016 7
Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Products under Investigation by Universities/Institutes, H2 2016 13
Recurrent Malignant Glioma - Pipeline by 2-BBB Medicines BV, H2 2016 14
Recurrent Malignant Glioma - Pipeline by AbbVie Inc, H2 2016 15
Recurrent Malignant Glioma - Pipeline by DNAtrix Inc, H2 2016 16
Recurrent Malignant Glioma - Pipeline by GtreeBNT Co Ltd, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Recurrent Malignant Glioma - Dormant Projects, H2 2016 42
Recurrent Malignant Glioma - Discontinued Products, H2 2016 43

List of Figures
Number of Products under Development for Recurrent Malignant Glioma, H2 2016 7
Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Top 10 Targets, H2 2016 19
Number of Products by Stage and Top 10 Targets, H2 2016 19
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Types, H2 2016 25

【レポートのキーワード】

再発性悪性神経膠腫

★調査レポート[再発性悪性神経膠腫:治療薬開発パイプライン動向(2016年下半期版)] (コード:DATA70209257)販売に関する免責事項を必ずご確認ください。
★調査レポート[再発性悪性神経膠腫:治療薬開発パイプライン動向(2016年下半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆